Lung

NSCLC Profiling by Multiplex Detection

Driven by FDA, NCCN and ASCO guidelines, our LUNGSEQ testing results associate Standard of Care therapeutics specific to NSCLC with a focus on prioritization and support of treatment planning for the physician

  • Comprehensive and integrated services mobilizing complete workups by PD-L1, FISH and Next Generation Sequencing
  • Available individual markers, reflexive offerings, and flexible testing designed to meet the cost efficiencies and clinical needs for the patient and physician
  • In-network with most managed care providers
  • 5-year survival rates for lung cancer are at 16.6%; 57% of lung cancers present at later stages with metastasis
  • A retorspective study noted 55% of classified and diagnosed lung tumors showed at least one oncological driver mutation or genomic arrangement potentially specific to an approved treatment
  • Identification of oncological drivers has redefined diagnostic workups
  • NCCN guidelines recommend individualized diagnostic strategies for NSCLC with NGS/multiplex testing to ensure patients receive the most appropriate treatment
  • Multiplexed genotyping identifies actionable drivers sooner and facilitates inclusion of new oncological drivers to existing panels

Learn more about our LUNGSEQ testing services.

How to Order
Test Directory
Requisition

Sample Report 

LungSEQicon-e1439838409219